Log in

3692 Hansoh Pharmaceutical Group Company Limited HKEX · China

Hansoh Pharmaceutical Group Company (3692) news

Hansoh Pharmaceutical Group Company Limited is a public biotech or pharmaceutical company listed on HKEX under the ticker 3692, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Hansoh Pharmaceutical Group Company news

We have not published a story on Hansoh Pharmaceutical Group Company yet. When there is news, it will appear here.

Questions about Hansoh Pharmaceutical Group Company

What is the ticker symbol of Hansoh Pharmaceutical Group Company?

Hansoh Pharmaceutical Group Company Limited trades under the ticker 3692 on HKEX.

Where is Hansoh Pharmaceutical Group Company listed?

Hansoh Pharmaceutical Group Company Limited is listed on HKEX. Our directory also records these other listings: GETTEX:3KY; LS:A2PLRC; SET:HANSOH19.

Which country or territory is Hansoh Pharmaceutical Group Company listed under?

Our directory records Hansoh Pharmaceutical Group Company Limited under China.

What does Hansoh Pharmaceutical Group Company do?

Our directory classifies Hansoh Pharmaceutical Group Company Limited as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Hansoh Pharmaceutical Group Company?

The ISIN recorded for Hansoh Pharmaceutical Group Company Limited is KYG549581067.

Does aibio.space cover Hansoh Pharmaceutical Group Company?

aibio.space lists Hansoh Pharmaceutical Group Company Limited among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Hansoh Pharmaceutical Group Company?

Companies in our directory listed in the same country and business area as Hansoh Pharmaceutical Group Company: Tibet Rhodiola Pharmaceutical Holding Co., Zhejiang Chengyi Pharmaceutical Co., Henan Taloph Pharmaceutical Stock Co., 3D Medicines, Kingchem (Liaoning) Life Science Co., Beijing TongRenTang Co..

Investor discussion: Hansoh Pharmaceutical Group Company

Members talk about Hansoh Pharmaceutical Group Company (3692). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Hansoh Pharmaceutical Group Company, newest first. Each line links the filing it comes from.

  1. Financings

    Share or debt issue: (1) PROPOSED RE-ELECTION OF DIRECTORS, (2) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES, (3) PROPOSED DECLARATION OF FINAL DIVIDEND, (4) PROPOSED RE-APPOINTMENT OF AUDITORS, (5) PROPOSED ADOPTION OF THE 2026 SHARE SCHEME AND (6) NOTICE OF ANNUAL GENERAL MEETING. Source

  2. Financings

    Share or debt issue: COMPLETION OF THE ISSUE OF HK$4,680 MILLION ZERO COUPON CONVERTIBLE BONDS DUE 2033. Source

  3. Financings

    Share or debt issue: PROPOSED ISSUE OF HK$4,680 MILLION ZERO COUPON CONVERTIBLE BONDS DUE 2033. Source

  4. Financings

    Share or debt issue: PLACING OF NEW SHARES UNDER GENERAL MANDATE ON FULLY UNDERWRITTEN BASIS. Source

  5. Financings

    Share or debt issue: (1) PROPOSED RE-ELECTION OF DIRECTORS, (2) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES, (3) PROPOSED DECLARATION OF FINAL DIVIDEND, (4) PROPOSED RE-APPOINTMENT OF AUDITORS AND (5) NOTICE OF ANNUAL GENERAL MEETING. Source

Press releases

Headlines of Hansoh Pharmaceutical Group Company's own announcements, newest first. Each opens the full release on the newswire that carried it.

  1. HKEXnews

    INSIDE INFORMATION - STRATEGIC COLLABORATION AND LICENSE AGREEMENT WITH ROCHE

  2. HKEXnews

    VOLUNTARY ANNOUNCEMENT - MARKETING AUTHORIZATION APPLICATION OF AUMOLERTINIB IN THE EU RESUBMITTED AND VALIDATED BY THE EMA

  3. HKEXnews

    VOLUNTARY ANNOUNCEMENT - UPDATE ON THE MARKETING AUTHORIZATION STATUS OF AUMOLERTINIB IN THE EU

  4. HKEXnews

    VOLUNTARY ANNOUNCEMENT - BIOLOGICS LICENSE APPLICATION OF RISVUTATUG REZETECAN FOR INJECTION (HS-20093) FOR OSTEOSARCOMA ACCEPTED BY THE NMPA

  5. HKEXnews

    NOTIFICATION LETTER TO NON-REGISTERED HOLDERS AND REQUEST FORM

  6. HKEXnews

    NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM

  7. HKEXnews

    VOLUNTARY ANNOUNCEMENT - RISVUTATUG REZETECAN FOR INJECTION (HS-20093) FOR OSTEOSARCOMA INCLUDED IN PRIORITY REVIEW AND APPROVAL PROCEDURE OF THE NMPA

  8. HKEXnews

    VOLUNTARY ANNOUNCEMENT - THE PHASE III CLINICAL STUDY OF HS-10374 IN THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS HAS MET THE CO-PRIMARY ENDPOINTS

  9. HKEXnews

    VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR HS-20197 FOR INJECTION ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

  10. HKEXnews

    VOLUNTARY ANNOUNCEMENT - RISVUTATUG REZETECAN FOR INJECTION (HS-20093) FOR SMALL CELL LUNG CANCER INCLUDED IN PRIORITY REVIEW AND APPROVAL PROCEDURE OF THE NMPA

  11. HKEXnews

    VOLUNTARY ANNOUNCEMENT - BIOLOGICS LICENSE APPLICATION OF HS-20093 FOR INJECTION FOR SMALL CELL LUNG CANCER ACCEPTED BY THE NMPA

  12. HKEXnews

    ADJUSTMENT TO CONVERSION PRICE OF THE CONVERTIBLE BONDS

  13. HKEXnews

    INTERIM DIVIDEND FOR THE SIX MONTHS ENDED JUNE 30, 2026

  14. HKEXnews

    INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026

  15. HKEXnews

    VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR HS-10582 TABLETS ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

  16. HKEXnews

    VOLUNTARY ANNOUNCEMENT - THE PHASE III CLINICAL STUDY OF HS-20093 IN THE TREATMENT OF OSTEOSARCOMA HAS MET THE PRIMARY ENDPOINT

  17. HKEXnews

    VOLUNTARY ANNOUNCEMENT - TRANSACTIONS WITH AVERE THERAPEUTICS

  18. HKEXnews

    VOLUNTARY ANNOUNCEMENT - THE PHASE III CLINICAL STUDY OF HS-20093 IN THE TREATMENT OF SMALL CELL LUNG CANCER HAS MET THE PRIMARY ENDPOINT

  19. HKEXnews

    VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVALS FOR HS-20136-2 INJECTION ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

  20. HKEXnews

    POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON FRIDAY, JUNE 26, 2026

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:3692 on TradingView.

Listing details

Hansoh Pharmaceutical Group Company Limited is a public biotech or pharmaceutical company listed on HKEX under the ticker 3692, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Hansoh Pharmaceutical Group Company Limited
Ticker
3692
Listing
HKEX
Country or territory
China
Business scope
Pharmaceuticals: Major
ISIN
KYG549581067
Other listed symbols
GETTEX:3KY; LS:A2PLRC; SET:HANSOH19
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.